How to Get Vyleesi (Bremelanotide) in Pennsylvania

What Is Vyleesi and Why Does Pennsylvania Access Matter?

Vyleesi (bremelanotide) is the only FDA-approved on-demand injectable treatment for acquired, generalized HSDD in premenopausal women. The FDA granted approval in June 2019 based on two Phase 3 RECONNECT trials enrolling 1,247 women across North America. In those trials, bremelanotide 1.75 mg subcutaneous injection produced a statistically significant increase in desire score (measured by the Female Sexual Function Index desire domain) and a meaningful reduction in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) compared with placebo [1].

Pennsylvania's regulatory environment is relatively favorable for women seeking bremelanotide. The state permits prescribing via telehealth, allows 503A compounding pharmacies to prepare and dispense the drug, and includes Vyleesi on its Medicaid formulary (with prior authorization). That combination of pathways means a patient in Pittsburgh, Philadelphia, or rural central PA can access the medication without an in-person specialist visit in most cases.

Still, practical barriers exist. Not every insurer covers brand-name Vyleesi, prior authorization paperwork varies by plan, and many primary care physicians have never written this prescription. The sections below walk through each step: finding a prescriber, completing labs, handling insurance, and receiving the medication at your door or local pharmacy.

Step 1: Finding a Prescriber in Pennsylvania

The fastest route is a telehealth consultation with a provider experienced in female sexual medicine. Pennsylvania law authorizes licensed physicians (MD/DO), certified registered nurse practitioners (CRNPs), and physician assistants (PAs) to prescribe controlled and non-controlled medications via synchronous audio-video visits [2]. Bremelanotide is not a scheduled substance under the DEA's Controlled Substances Act, so it does not require an in-person exam or state-specific controlled substance telehealth restrictions.

What should you look for in a telehealth provider? First, confirm the clinician holds an active Pennsylvania license. Second, verify they have experience diagnosing HSDD rather than simply writing prescriptions for sexual health products. The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care algorithm in 2018 that guides clinicians through differential diagnosis, ensuring situational or relationship-related concerns are distinguished from generalized, acquired HSDD [3].

In-person options include gynecologists and sexual medicine specialists at academic centers such as Penn Medicine in Philadelphia, UPMC in Pittsburgh, and Geisinger in Danville. A referral is not typically required by insurers for a gynecology visit, though some HMO plans in the state do require one.

Step 2: Required Labs and Clinical Evaluation

No single lab panel is mandated by the FDA label before prescribing bremelanotide. The label does state that Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [4]. A baseline blood pressure check is standard. Most prescribers will also order a focused lab panel to rule out medical causes of low desire.

A typical pre-Vyleesi workup includes thyroid-stimulating hormone (TSH), prolactin, total and free testosterone, estradiol, and a complete metabolic panel. The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women recommends measuring total testosterone when evaluating female sexual dysfunction, primarily to exclude androgen deficiency or excess as a contributing factor [5]. Prolactin elevation from medications such as SSRIs or antipsychotics can independently suppress desire, so identifying that cause may change the treatment plan entirely.

Blood pressure deserves particular attention. In the RECONNECT trials, bremelanotide produced a transient mean increase of 6 mmHg systolic and 3 mmHg diastolic within 2 to 3 hours of dosing, returning to baseline within 12 hours [1]. The effect was more pronounced in women with pre-existing hypertension. The FDA label recommends against use in women with uncontrolled hypertension and advises blood pressure monitoring in women with controlled hypertension or cardiovascular risk factors [4].

Pennsylvania telehealth providers can accept lab results from any CLIA-certified lab. Quest Diagnostics and Labcorp both operate draw sites across the state, and many telehealth platforms will order labs electronically so patients can walk in without an appointment.

Step 3: Understanding the HSDD Diagnosis

HSDD is defined in the DSM-5 (under Female Sexual Interest/Arousal Disorder) as a persistent or recurrent deficiency of sexual desire that causes marked personal distress and is not better explained by another mental disorder, a medical condition, substance use, or relationship distress [6]. The "acquired, generalized" qualifier in Vyleesi's indication means the condition developed after a period of normal desire and occurs across situations rather than being limited to a specific partner or context.

Clinicians typically use validated instruments to quantify severity. Short forms are common. The Female Sexual Distress Scale-Revised (FSDS-R) Item 13, which specifically asks about distress related to low desire, is the most widely cited single-item screener [7]. A score of 2 or higher (on a 0 to 4 scale) indicates clinically significant distress. In the RECONNECT trial, patients had a mean baseline FSDS-DAO score of approximately 30, reflecting substantial burden, and the bremelanotide group experienced a mean reduction of 10.4 points versus 7.6 for placebo (P<0.001) [1].

Diagnosis is often straightforward but requires a conversation many clinicians find uncomfortable. A 2020 survey published in the Journal of Sexual Medicine found that only 14% of ob-gyn residents received formal training in female sexual dysfunction during residency [8]. This gap partly explains why telehealth platforms staffed by sexual medicine specialists have become a preferred access point.

Step 4: Insurance Coverage and Prior Authorization in Pennsylvania

Coverage varies by payer. Here is a breakdown of the major channels.

Commercial insurance. Most large commercial plans in Pennsylvania (Highmark, Independence Blue Cross, Aetna, Cigna, UPMC Health Plan) classify Vyleesi as a specialty drug requiring prior authorization. The standard PA criteria across these plans generally require documentation of: (1) an HSDD diagnosis by a qualified provider, (2) the patient is premenopausal, (3) the condition is acquired and generalized, and (4) the patient has tried or has a contraindication to flibanserin (Addyi), the oral daily alternative [9]. Some plans waive the flibanserin step-therapy requirement when the prescriber documents a clinical reason favoring on-demand dosing over daily therapy.

Pennsylvania Medicaid (Medical Assistance). Vyleesi is covered under the state's fee-for-service and managed care formularies with prior authorization. PA Medicaid's preferred drug list requires the same general criteria as commercial plans. Processing times for Medicaid PA in Pennsylvania average 3 to 5 business days for standard requests and 24 hours for expedited requests [10].

Cash pay. Without insurance, brand-name Vyleesi costs approximately $900 to $1,000 per 4-autoinjector carton at retail pharmacies. Palatin Technologies offers a manufacturer copay card that can reduce out-of-pocket costs for commercially insured patients to as low as $50 per fill. Patients using 503A compounding pharmacies may find lower per-dose pricing (typically $80 to $200 per month depending on the pharmacy and dose count), though compounded bremelanotide is prepared from bulk drug substance and is not FDA-approved in compounded form.

Prior authorization documentation checklist:

• Signed letter of medical necessity from the prescriber
• HSDD diagnosis with ICD-10 code F52.0
• Documentation that the patient is premenopausal
• Lab results (if requested by plan) confirming no untreated hormonal cause
• Record of prior therapy trial or contraindication to flibanserin
• Prescriber NPI and Pennsylvania license number

Step 5: Pharmacy Options in Pennsylvania

Pennsylvania patients have three main dispensing pathways.

Retail/specialty pharmacy. Brand-name Vyleesi (manufactured by Palatin Technologies, distributed by AMAG Pharmaceuticals) is stocked at national specialty pharmacies including Accredo, CVS Specialty, and OptumRx Specialty. Some retail pharmacies can special-order it. The autoinjector arrives as a prefilled, single-use device stored at room temperature.

503A compounding pharmacies. Pennsylvania's State Board of Pharmacy licenses 503A compounding pharmacies to prepare patient-specific prescriptions. Several compounding pharmacies in the state compound bremelanotide from bulk API for subcutaneous injection. These pharmacies can ship within Pennsylvania to the patient's address. Compounded bremelanotide is typically dispensed in multi-use vials with syringes rather than autoinjectors, so patients must be comfortable with manual injection technique. The FDA's guidance on 503A compounding permits this pathway as long as the pharmacy holds a valid state license and compounds pursuant to a valid patient-specific prescription [11].

Mail-order specialty. Most insured patients receive Vyleesi through their plan's preferred specialty mail-order pharmacy. Shipping is typically overnight or 2-day, temperature-controlled, and included at no extra cost. Turnaround from PA approval to delivery averages 3 to 5 business days.

Step 6: Self-Injection Technique and Timing

Bremelanotide is administered as a 1.75 mg subcutaneous injection in the abdomen or thigh at least 45 minutes before anticipated sexual activity [4]. The autoinjector simplifies the process: remove the cap, press to the skin at a 90-degree angle, press the button, hold for 5 seconds. The injection volume is 0.3 mL.

The most common side effects in the RECONNECT trials were nausea (40.0% bremelanotide vs. 1.3% placebo), flushing (20.3% vs. 1.5%), and injection-site reactions (5.4% vs. 3.3%) [1]. Nausea was the primary reason for discontinuation, occurring in 7.5% of bremelanotide-treated patients. An important pattern emerged in the trial data: nausea severity decreased with repeated dosing. By the third dose, most women who experienced nausea at the first dose reported it as mild or absent [1].

Practical tips from clinical experience: eating a light meal 1 to 2 hours before injection may reduce nausea intensity. Antiemetic pretreatment with ondansetron 4 mg has been used off-label by some prescribers, though this is not part of the labeled instructions. Rotating injection sites reduces the likelihood of local reactions. The drug should not be used more than once in 24 hours or more than 8 times in a calendar month.

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials and professor of reproductive biology at Case Western Reserve University, stated: "Bremelanotide addresses a real unmet need because it works on demand, which aligns with how many women actually experience and plan for intimacy" [1].

Step 7: Timeline From Consultation to First Dose

A realistic timeline for a Pennsylvania patient using telehealth:

• Day 1: Complete online intake and schedule video consultation (same-day or next-day appointments are common).
• Days 1 to 3: Telehealth visit, lab order placed.
• Days 3 to 7: Labs drawn and results reviewed by prescriber.
• Days 5 to 10: Prescription sent to pharmacy, prior authorization submitted (if insured). Cash-pay prescriptions skip this step.
• Days 7 to 14: PA approved (or appeal filed if denied). Medication shipped or picked up.

Total time from first click to first dose: 5 to 14 days for most patients. Delays occur most often at the prior authorization stage. If a PA is denied, the prescriber can file a peer-to-peer review with the insurance medical director within 1 to 2 business days.

Safety Monitoring After Starting Vyleesi

The FDA label recommends a follow-up blood pressure check for patients with cardiovascular risk factors [4]. In clinical practice, most prescribers schedule a follow-up visit (telehealth or in-person) at 4 to 6 weeks to assess efficacy, tolerability, and blood pressure.

Long-term data from the open-label extension of RECONNECT showed that bremelanotide maintained efficacy through 12 months of as-needed use, with no new safety signals [12]. Focal skin hyperpigmentation, caused by melanocortin-1 receptor activation, occurred in approximately 1% of patients. This effect is generally mild, reversible upon discontinuation, and more common in patients with darker baseline skin tones. The FDA label specifically notes this risk and recommends that patients perform a baseline skin examination and report any new or changing pigmented lesions [4].

Dr. Anita Clayton, professor of psychiatry and neurobehavioral sciences at the University of Virginia, noted in a 2019 review: "The melanocortin pathway is a fundamentally different mechanism from flibanserin's serotonergic approach, and the on-demand dosing model reduces cumulative drug exposure compared with daily regimens" [13].

Pennsylvania-Specific Regulatory Considerations

Pennsylvania does not impose additional state-level restrictions on bremelanotide beyond federal requirements. Several points are worth clarifying.

Telehealth prescribing authority. Act 15 of 2020 expanded Pennsylvania's telehealth laws, confirming that any service deliverable in person may be delivered via telehealth unless specifically excluded [2]. Bremelanotide prescribing is not excluded. CRNPs in Pennsylvania with a collaborative agreement (or practicing independently under Act 68 of 2022) may prescribe Vyleesi without physician co-signature.

Compounding pharmacy shipping. Pennsylvania 503A pharmacies may ship compounded bremelanotide to patients within the state. Interstate shipment of 503A-compounded products is restricted under federal law unless the pharmacy also holds 503B outsourcing facility registration. Patients who move or travel out of state should verify that their compounding pharmacy can legally ship to their new location.

Prescription transfer. A Vyleesi prescription written in another state can be transferred to a Pennsylvania pharmacy as long as the prescribing provider's license is verified and the pharmacy accepts out-of-state transfers. Pennsylvania Board of Pharmacy regulations permit this for non-controlled substances [14]. The prior authorization, however, does not transfer. A new PA must be filed with the Pennsylvania-based insurer.